title: Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
abstract: Atypical antipsychotics can alleviate the severity of tardive dyskinesia, but few studies have monitored their long-term effects. The present study investigated the effect of risperidone on pre-existing severe tardive dyskinesia among 40 patients with chronic schizophrenia over 48 weeks. The total Abnormal Involuntary Movement Scale (AIMS) score decreased in 35 patients (87.5%) and increased in three patients (7.5%). At the end of the 48-week trial, the mean total AIMS score decreased significantly, from 15.7+/-4.7 (baseline) to 10.6+/-4.4 (P<0.001), with a mean risperidone dosage of 3.6+/-1.5 mg/day. Twenty-three patients (57.5%) were responders with an average total AIMS score decrease of 8.0+/-2.7. Multiple logistic regression analysis controlling for age, gender, duration of illness, index hospitalization duration, risperidone dose, anticholinergic concomitant use and dystonia score change revealed that a change in the parkinsonism score was the most significant factor related to responders (odds ratio 3.476, 95% confidence interval 1.173-10.298). A significant improvement observed in tardive dyskinesia was noted at week 8, and this improvement persisted until week 48. The results show that the effect of risperidone on pre-existing tardive dyskinesia may be beneficial.
authors.affiliation: Institute of Public Health, National Yang-Ming University, Taipei, Taiwain.
authors.forename: Ya-Mei
authors.initials: YM
authors.lastname: Bai
authors.forename: Shun-Chieh
authors.initials: SC
authors.lastname: Yu
authors.forename: Jen-Yeu
authors.initials: JY
authors.lastname: Chen
authors.forename: Chih-Yuan
authors.initials: CY
authors.lastname: Lin
authors.forename: Pesus
authors.initials: P
authors.lastname: Chou
authors.forename: Chao-Cheng
authors.initials: CC
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012702:Serotonin Antagonists / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D012702:Serotonin Antagonists; D018967:Risperidone